Condition: Methamphetamine Use Disorder · Sponsor: Kevin Murnane
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
This description comes directly from the study's public registry record.
Kevin S Murnane, PhD · (318) 675-7830 · kevin.murnane@lsuhs.edu
John A Vanchiere, MD, PhD · (318)675-7103 · john.vanchiere@lsuhs.edu
Always discuss trial participation with your own doctor first.
| LSU Health Shreveport | Shreveport, Louisiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06899594